IL13 and asthma: Biologics such as IL-5 and IL-5R (mepolizumab, reslizumab, and benralizumab) and the IL-4 receptor subunit α of IL-4 shared by the IL-4 and IL-13 receptor complexes, thereby inhibiting IL-4 and IL-13 signaling (dupilumab), have shown significant efficacy in reducing asthma exacerbations, improving lung function, and enhancing the quality of life (QoL) for patients with severe asthma.